This finding is basically consistent with previous evidence, while inconsistency exists probably due to the disparity in cancer types or experimental conditions.17,45 Considering the accumulating evidence that PRDX1 is involved in various cancer types, and ROS elevation is frequently observed in cancer cells treated with Celastrol, it is likely that PRDX1 might be the primary target protein of Celastrol in other cancer types with ROS abnormality, in addition to the colorectal cancer proved here. This evidence concerns the gene PRDX1 and cancer.